Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Rohit Thummalapalli, MD"'
Autor:
Rohit Thummalapalli, MD, Noura J. Choudhury, MD, Fiona Ehrich, MS, Tyler Beardslee, PharmD, Danielle Brazel, MD, Shannon S. Zhang, MD, Shelby Merchant, PharmD, Monica F. Chen, MD, Glenn Heller, PhD, Suresh S. Ramalingam, MD, Sai-Hong Ignatius Ou, MD, PhD, Kathryn F. Mileham, MD, Gregory J. Riely, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 8, Pp 100546- (2023)
Introduction: Treatment with lorlatinib for patients with advanced ALK- and ROS1-rearranged NSCLC (ALK+ and ROS1+ NSCLC) is associated with a unique set of adverse events (AEs) often requiring dose reduction. However, the impact of dose reductions on
Externí odkaz:
https://doaj.org/article/4a17b716e5554aaa9e42589db4af6e82
